Orexigen conquers French objections to obesity drug with EU approval
This article was originally published in Scrip
Executive Summary
Orexigen has overcome objections from France to receive European Commission approval for its obesity product Mysimba (naltrexone HCl / bupropion HCl prolonged release) in all 28 EU member states.
You may also be interested in...
UK’s NICE Rejects Use Of Orexigen’s Mysimba For Obesity
Consilient, which markets Orexigen’s obesity drug Mysimba in the UK and Ireland, says it is “extremely disappointed” by NICE’s decision to reject the product for use on the NHS. NICE said it had concerns over the drug’s long-term effectiveness and its ability to offer value to the health service.
Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.